TrialCancer immunology, immunotherapy : CII1993

Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study.

A Lindemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.